Oncology Central

KEYNOTE-048: pembrolizumab changes the rules for head and neck cancer patients

0
The KEYNOTE-048 study has demonstrated that immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer. The findings could make immunotherapy become a standard, first-line treatment for advanced head and neck cancer, and spare many patients the side-effects associated with combination chemotherapy.
At the ESMO 2018 Congress (19–23 October 2018, Munich, Germany) we had the pleasure of speaking with first author Barbara Burtness (Yale School of Medicine, CT, USA) about the trial and what further advances she envisages with respect to head and neck cancer, as well as immuno-oncology, in the coming years.
  1. Could you provide us an overview of the KEYNOTE-048 trial and the results that were recently presented at ESMO?
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.